CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

1 year ago

- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society…

2024 Tsingke High-Impact Literature Compilation – Gene Synthesis

1 year ago

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number…

MintNeuro Secures £1M Investment to Advance Transformative Semiconductor Technology for Neural Implants

1 year ago

 Latest capital raise will accelerate delivery of silicon roadmap to drive next-generation implantable devices for neurological applications LONDON, Nov. 12,…

Spencer Trask Venture Good Measures Acquired by NationsBenefits, Bringing Personalized Nutrition to Millions

1 year ago

GREENWICH, Conn., Nov. 11, 2024 /PRNewswire/ -- Spencer Trask & Co., an advanced technology development firm, announced today that its…

Bunkerhill Health AI Powers Cardiovascular Screening at Stamford Health

1 year ago

SAN FRANCISCO, Oct. 21, 2024 /PRNewswire/ -- Stamford Health's Heart & Vascular Institute has announced it will be the first in…

Perceptive eClinical Launches ClinPhone 5: A Ground-breaking new RTSM Platform Delivering a Leap in Clinical Development Technology

1 year ago

Platform developed in collaboration with CRScube, capitalizing on learnings from world-leading pharma and biotech companies NOTTINGHAM, England, Nov. 11, 2024 /PRNewswire/…

MyndTec Announces Exclusive License Agreement with Albany Medical College for AI-Based Spinal Cord Stimulation Technology

1 year ago

Mississauga, Ontario--(Newsfile Corp. - November 11, 2024) - MyndTec Inc (CSE: MYTC). ("MyndTec" or the "Company"), a medical technology company…

Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

1 year ago

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today…

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

1 year ago

Top-line results compared to baseline at six months: Median apnea-hypopnea index reduction of 66.2% Median oxygen desaturation index reduction of…